Tactic Pharma LLC Amends Monopar Therapeutics Stake

Ticker: MNPR · Form: SC 13D/A · Filed: 2024-12-17T00:00:00.000Z

Sentiment: neutral

Topics: ownership-change, sec-filing, amendment

Related Tickers: CPRX

TL;DR

Tactic Pharma just updated their Monopar Therapeutics holdings. Big move incoming?

AI Summary

Tactic Pharma LLC, through an amendment filed on December 17, 2024, has updated its Schedule 13D regarding Monopar Therapeutics Inc. The filing indicates a change in beneficial ownership, with Tactic Pharma LLC now holding a significant stake in the company. The specific percentage and number of shares are detailed within the full filing.

Why It Matters

This amendment signals a potential shift in control or influence over Monopar Therapeutics, which could impact its strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can precede significant corporate actions, introducing uncertainty and potential volatility.

Key Players & Entities

FAQ

What is the exact percentage of Monopar Therapeutics' common stock that Tactic Pharma LLC beneficially owns after this amendment?

The filing does not explicitly state the exact percentage of beneficial ownership in the provided text, but it is an amendment to a Schedule 13D, indicating a change in ownership that crosses a reporting threshold.

When was the previous Schedule 13D filing by Tactic Pharma LLC or its group members?

The provided text is an amendment (Amendment No. 1) filed on December 17, 2024, indicating a prior filing existed but its date is not specified here.

What is the business address of Tactic Pharma LLC?

The business address for Tactic Pharma LLC is 598 Rockefeller Rd., Lake Forest, IL, 60045.

Who are the individuals listed as group members in this filing?

The individuals listed as group members are Andrew Mazar, Chandler Robinson, Michael Brown, and Thomas O'Halloran.

What is the CUSIP number for Monopar Therapeutics Inc. common stock?

The CUSIP number for Monopar Therapeutics Inc. common stock is 61023L207.

From the Filing

0001437749-24-037745.txt : 20241217 0001437749-24-037745.hdr.sgml : 20241217 20241217170142 ACCESSION NUMBER: 0001437749-24-037745 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20241217 DATE AS OF CHANGE: 20241217 GROUP MEMBERS: ANDREW MAZAR GROUP MEMBERS: CHANDLER ROBINSON GROUP MEMBERS: MICHAEL BROWN GROUP MEMBERS: THOMAS O'HALLORAN SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-94081 FILM NUMBER: 241556521 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Tactic Pharma LLC CENTRAL INDEX KEY: 0001727357 ORGANIZATION NAME: IRS NUMBER: 272312444 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 598 ROCKEFELLER RD. CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: 4158279929 MAIL ADDRESS: STREET 1: C/O SKOKIE BLVD., SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 SC 13D/A 1 tpllc20241217_sc13da.htm SCHEDULE 13D/A tpllc20241217_sc13da.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MONOPAR THERAPEUTICS INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 61023L207 (CUSIP Number) Tactic Pharma LLC c/o 1000 Skokie Blvd, Ste 350, Wilmette, IL, 60091 (847) 388-0349 (Name, address and telephone number of person authorized to receive notices and communications) December 9, 2024 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box .☐ The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes) CUSIP No. 61023L207 1 NAME OF REPORTING PERSONS Tactic Pharma LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ 3 SEC USE ONLY 4 SOURCE OF FUNDS OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐ 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 855,589 8 SHARED VOTING POWER 0.00 9 SOLE DISPOSITIVE POWER 855,589 10 SHARED DISPOSITIVE POWER 0.00 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 855,589 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 16.2% 14 TYPE OF REPORTING PERSON OO CUSIP No. 61023L207 1 NAME OF REPORTING PERSONS ANDREW MAZAR 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ 3 SEC USE ONLY 4 SOURCE OF FUNDS OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐ 6 CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 1 8 SHARED VOTING POWER 855,589 9 SOLE DISPOSITIVE POWER 1 10 SHARED DISPOSITIVE POWER 855,589 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 855,590 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐ 13 PERCENT OF CLASS REPRESE

View on Read The Filing